Polycation cytotoxicity a delicate matter for nucleic acid therapy—focus on polyethylenimine

Purpose: Efficient transfection with low toxicity is essential for nucleic acid therapeutics, but synthetic polycations such as polyethylenimine (PEI) are limited by cytotoxicity. This review critically assesses the safety and efficacy challenges of PEI-based polyplexes, identifies deficiencies in the field, and proposes avenues for designing safer polycationic vectors for clinical gene therapy and RNA interference delivery.

Hypothesis: This is a review article and does not test a single formal hypothesis. Its central premise is that PEI-induced cytotoxicity is multifaceted — involving membrane perturbation, lysosomal damage, mitochondrial permeabilization, ER/Golgi stress, apoptotic and necrotic pathways — and that rational design of safer polycations requires real-time, single-cell, mechanistic, and toxicogenomic studies rather than simple viability assays.

Aims: Provide a critical assessment of challenges facing nucleic acid therapeutics, focusing on synthetic polycations and PEI. - Review classical views on polyplex uptake mechanisms and cytoplasmic entry, including the disputed proton-sponge hypothesis. - Discuss polyplex-mediated membrane perturbation events and how they relate to cytoplasmic entry versus cytotoxicity. - Examine nuclear entry, toxicogenomics, and designer PEI conjugates. - Identify neglected areas and propose future studies to clarify internalization, trafficking, toxicity, and ultimate polycation fate.

Delivery system: Polymer: Polyethylenimine (PEI), linear and branched forms; molecular weights from a few hundred Da to 1500 kDa; 25 kDa branched PEI is among the most efficient but also most cytotoxic. - Vector type: Polyplexes formed by electrostatic condensation of cationic PEI with anionic nucleic acids. - Payloads: Genetic materials, including plasmid DNA and RNAi therapeutics (siRNA, etc.). - PEI conjugates/modifications: Cross-linked PEI with degradable linkages (disulfide, ester, acetal, orthoester), PEGylated PEI, cholesterol-PEI, PEI-cyclodextrin, poly(ethylene imine sulfide), PEI-chitosan, PEI-polyester, and others listed in Table 2. - Targeting/functional features: Folate decoration for caveolar uptake, degradable linkers for reduced cytotoxicity, and various low-molecular-weight PEI assemblies.

Approach: Critical review of in vitro and in vivo literature. Discusses cell types, isolated mitochondria, supported lipid bilayers, and tumour xenograft models (e.g., A431 with linear PEI). No new primary experiments, group sizes, or doses are reported. The review notes that in vivo developments in the field remain scant and that major studies are required.

Key methods: MTT assay and related viability assays (noted as limited for detecting programmed cell death). - Lactate dehydrogenase (LDH) leakage for membrane damage. - Phosphatidylserine redistribution without caspase-3 activation. - Caspase activation and apoptotic pathway analysis. - Isolated mitochondrial cytochrome c release. - Supported lipid bilayer studies for membrane thinning, pore formation, and defects. - Microarray-based gene expression profiling for toxicogenomics. - Real-time kinetics and single-cell level analysis proposed as needed.

Key results: Branched 25 kDa PEI is among the most efficient polycationic transfectants but also among the most cytotoxic. - PEI polyplexes damage plasma membranes, causing phosphatidylserine redistribution and LDH leakage without caspase-3 activation. - Theoretical calculation: a 200 nm vesicle containing one polyplex with 5 plasmid DNA molecules of 5000 bp would expand membrane area by only 2.5%, below the 5% strain threshold for lipid vesicle integrity, questioning the proton-sponge hypothesis. - Minimum PEI concentration for cytochrome c release from isolated mitochondria was 0.1 µg/mL. - Intratumoural linear PEI in A431 tumour xenografts affected 374 genes: 124 upregulated and 250 downregulated; branched PEI effects were more severe and correlated with greater toxicity. - MTT assay may give false-positive viability results because MTT reduction is not restricted to mitochondria and is not a direct measure of programmed cell death.

Interpretation: Cytotoxicity remains a major clinical concern for synthetic cationic transfectants. Understanding of polycation toxicity has not advanced systematically; in vivo safety and efficacy data are lacking. PEI-mediated cytotoxicity involves complex membrane perturbation and organelle damage, with mitochondrial permeabilization as a central integrator of death pathways. MTT assays alone are insufficient to declare “less cytotoxic” PEI derivatives safe. Real-time mechanistic studies, toxicogenomic assessment, and in vivo validation are required to design safer “genocompatible” polycations with an improved benefit-to-risk ratio.

Limitations: This is a review, not a primary study; no new experimental data or meta-analysis. - Many proposed mechanisms remain speculative or disputed, especially the proton-sponge hypothesis. - Lack of standardized, mechanism-based toxicity assays; MTT is overused and can be misleading. - In vivo investigations of “less cytotoxic” PEI derivatives are scarce. - Long-term fate, exocytosis, genotoxicity of fragments, and effects on proteasome function are unresolved. - No large-animal or clinical validation is presented. - The review identifies numerous unanswered questions rather than providing definitive conclusions.